Related Experiment Video

Updated: Aug 25, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Nebulized salbutamol vs salbutamol and ipratropium combination in asthma

Anita Sharma1, Arvind Madaan

  • 1Department of Pediatrics, Pt. B.D. Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India. dr_anitassharma@sifymail.com

Indian Journal of Pediatrics
|April 1, 2004
PubMed

Insights

Combined nebulization with salbutamol and ipratropium bromide offers additional benefits for children experiencing moderate acute asthma attacks. This frequent treatment approach demonstrates improved outcomes compared to salbutamol alone.

Area of Science:

  • Pediatric Pulmonology
  • Emergency Medicine
  • Pharmacology

Background:

  • Acute asthma attacks in children require effective and timely treatment.
  • Nebulized bronchodilators are a cornerstone of asthma exacerbation management.
  • Assessing the synergistic effects of combined therapies can optimize treatment protocols.

Purpose of the Study:

  • To evaluate the added benefit of frequent nebulization with salbutamol and ipratropium bromide.
  • To compare the efficacy of combined nebulization versus salbutamol alone in moderate acute asthma.
  • To determine the impact on respiratory function parameters in pediatric patients.

Main Methods:

  • A randomized study involving 50 children aged 6-14 years with moderate acute asthma.
  • Group I received three doses of salbutamol alone via nebulization.
  • Group II received three doses of combined salbutamol and ipratropium bromide via nebulization at 20-minute intervals.
  • Patients were observed for changes in Peak Expiratory Flow Rate (PEFR) over 4 hours.

Main Results:

  • Both treatment groups showed significant improvement in %PEFR from 30 minutes to 4 hours.
  • The group receiving combined salbutamol and ipratropium bromide demonstrated superior results.
  • Statistical analysis indicated a significant benefit of the combination therapy.

Conclusions:

  • Frequent combined nebulization with salbutamol and ipratropium bromide is beneficial for moderate acute asthma in children.
  • This combination therapy provides an additional advantage over salbutamol alone.
  • The findings support the use of combined nebulization for enhanced asthma exacerbation management.
Abstract

More Related Videos

Methodology for Sputum Induction and Laboratory Processing13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...